ATE380543T1 - Stabilisierung von festen schilddrüsenhormonzusammensetzungen - Google Patents

Stabilisierung von festen schilddrüsenhormonzusammensetzungen

Info

Publication number
ATE380543T1
ATE380543T1 AT01971348T AT01971348T ATE380543T1 AT E380543 T1 ATE380543 T1 AT E380543T1 AT 01971348 T AT01971348 T AT 01971348T AT 01971348 T AT01971348 T AT 01971348T AT E380543 T1 ATE380543 T1 AT E380543T1
Authority
AT
Austria
Prior art keywords
stabilization
thyroid hormone
forms
excipients
moisture
Prior art date
Application number
AT01971348T
Other languages
English (en)
Inventor
Spiridon Spireas
Original Assignee
Sigmapharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigmapharm Inc filed Critical Sigmapharm Inc
Application granted granted Critical
Publication of ATE380543T1 publication Critical patent/ATE380543T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01971348T 2000-10-03 2001-09-26 Stabilisierung von festen schilddrüsenhormonzusammensetzungen ATE380543T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23744200P 2000-10-03 2000-10-03
US09/690,973 US6855333B1 (en) 2000-10-03 2000-10-18 Stabilization of solid thyroid drug formulations

Publications (1)

Publication Number Publication Date
ATE380543T1 true ATE380543T1 (de) 2007-12-15

Family

ID=26930677

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01971348T ATE380543T1 (de) 2000-10-03 2001-09-26 Stabilisierung von festen schilddrüsenhormonzusammensetzungen

Country Status (13)

Country Link
US (1) US6855333B1 (de)
EP (1) EP1322294B1 (de)
CN (1) CN1543341A (de)
AT (1) ATE380543T1 (de)
AU (2) AU9124401A (de)
CA (4) CA2641575C (de)
CY (1) CY1107295T1 (de)
DE (1) DE60131863T2 (de)
ES (1) ES2298262T3 (de)
MX (1) MXPA03002809A (de)
NZ (1) NZ524567A (de)
PT (1) PT1322294E (de)
WO (1) WO2002028364A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
WO2002072069A1 (en) * 2001-03-12 2002-09-19 Novo Nordisk A/S Novel tablets and capsules and a process for its preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
US10231931B1 (en) 2018-03-23 2019-03-19 Genus Lifesciences Inc. Thyroid hormone oral dosage forms and methods of using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001211A (en) * 1974-12-02 1977-01-04 The Dow Chemical Company Pharmaceutical capsules from improved thermogelling methyl cellulose ethers
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5051406A (en) 1987-03-04 1991-09-24 Nippon Hypox Laboratories Incorporated Pharmaceutical composition using albumin as a carrier and process for producing the same
US4983399A (en) * 1989-10-18 1991-01-08 Eastman Kodak Company Direct compression carrier composition
US5225204A (en) * 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
DE4318577A1 (de) 1993-06-04 1994-12-08 Merck Patent Gmbh Schmiermittelfreie, arzneimittelhaltige Tabletten
WO1995013794A1 (en) 1993-11-18 1995-05-26 Nippon Shinyaku Co., Ltd. Process for producing stable medicinal composition, and pharmaceutical preparation
GB9401892D0 (en) 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
IL115445A (en) 1994-10-17 1999-08-17 Akzo Nobel Nv Solid pharmaceutical compositions comprising low dosage active ingredient oil and excipient capable of binding water and their preparation
US5756123A (en) * 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
DE19541128C2 (de) 1995-10-27 1997-11-27 Henning Berlin Gmbh & Co Stabilisierte schilddrüsenhormonhaltige Arzneimittel
US5635209A (en) 1995-10-31 1997-06-03 Vintage Pharmaceuticals, Inc. Stabilized composition of levothyroxine sodium medication and method for its production
AU712217B2 (en) 1995-11-14 1999-11-04 Abbott Gmbh & Co. Kg Stabilized thyroid hormone preparations and methods of making same
IL126580A (en) 1996-04-16 2001-08-08 Bayer Ag D- Manitol and its preparation
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same

Also Published As

Publication number Publication date
CA2423572A1 (en) 2002-04-11
CA2641570C (en) 2014-04-22
AU9124401A (en) 2002-04-15
CN1543341A (zh) 2004-11-03
CA2641570A1 (en) 2002-04-11
CA2641581C (en) 2011-11-29
MXPA03002809A (es) 2004-09-10
HK1055260A1 (en) 2004-01-02
DE60131863D1 (de) 2008-01-24
CA2641575A1 (en) 2002-04-11
WO2002028364A3 (en) 2002-06-06
NZ524567A (en) 2004-12-24
CA2423572C (en) 2009-01-06
CA2641581A1 (en) 2002-04-11
PT1322294E (pt) 2008-02-28
EP1322294A2 (de) 2003-07-02
DE60131863T2 (de) 2008-12-11
EP1322294B1 (de) 2007-12-12
CA2641575C (en) 2014-04-08
ES2298262T3 (es) 2008-05-16
AU2001291244B2 (en) 2006-09-21
WO2002028364A2 (en) 2002-04-11
CY1107295T1 (el) 2012-11-21
US6855333B1 (en) 2005-02-15

Similar Documents

Publication Publication Date Title
CY1107295T1 (el) Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους
MXPA03002807A (es) Estabilizacion de formulaciones solidas de farmacos.
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
DE60231298D1 (de) Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen
EA200301275A1 (ru) Капсулы для ингаляции
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
DK0949907T3 (da) Fremgangsmåder og præparater til forbedret biotilgængelighed og biologisk aktive midler til slimhindeadministration
ATE356612T1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
SE0003449D0 (sv) Anticancer compositions
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
DK1318788T3 (da) Nanopartikulær fastdosissammensætninger
AU2003274681A8 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
ATE350013T1 (de) Nanopartikelzusammensetzungen enthaltend insulin
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
IL151311A0 (en) Pharmaceutical compositions containing propofol
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
BG106368A (en) Pharmaceutical composition and its preparation
DK1273301T3 (da) Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration
WO2004014318A3 (en) Levothyroxine compositions and methods
GB0018322D0 (en) Pharmaceutical compositions
SE0203817D0 (sv) New composition

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1322294

Country of ref document: EP